Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Elicio Therapeutics, Inc. (ANGN)
|
Add to portfolio |
|
|
|
| Price: |
$2.96
| | Metrics |
| OS: |
30.1
|
M
| |
-117
|
% ROE
|
| Market cap: |
$89.1
|
M
| |
-132
|
% ROIC
|
|
Net cash:
|
$21.7
|
M
| |
$0.72
|
per share
|
|
EV:
|
$67.5
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($23.6)
|
M
| |
|
|
|
EBIT
|
($22.5)
|
M
| |
|
|
| EPS |
($3.28)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| Revenues | 2.3 | 28.3 | 2.9 | 1.5 | 4.0 |
| Revenue growth | -91.9% | 883.1% | 93.7% | -63.1% | |
| Cost of goods sold | 0.0 | 0.4 | 0.0 | 0.0 | 18.4 |
| Gross profit | 2.3 | 27.9 | 2.9 | 1.5 | -14.3 |
| Gross margin | 100.0% | 98.5% | 100.0% | 100.0% | -356.0% |
| Research and development | 18.1 | 48.7 | | | |
| General and administrative | 14.6 | 18.5 | 18.0 | 9.6 | 5.4 |
| EBIT | -30.4 | -39.3 | -55.3 | -38.6 | -14.2 |
| EBIT margin | -1322.7% | -138.8% | -1921.2% | -2595.2% | -352.3% |
| Pre-tax income | -38.8 | -54.6 | -80.1 | -40.7 | -20.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -38.8 | -54.6 | -80.1 | -40.7 | 0.0 |
| Net margin | -1686.5% | -192.8% | -2781.5% | -2734.2% | -0.6% |
| |
| Diluted EPS | ($1.29) | ($1.93) | ($5.43) | ($2.82) | ($2.58) |
| Shares outstanding (diluted) | 30.0 | 28.2 | 14.8 | 14.4 | 0.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|